PHAR Stock Analysis — PHARMING GROUP NV (Healthcare >> Biotechnology)
PHAR FAQ
What is PHAR's P/E ratio?
PHARMING GROUP NV (PHAR) currently trades at a P/E ratio of 43.37.
What is PHAR's ROE?
PHARMING GROUP NV reports a Return on Equity (ROE) of 4.58%.
What is PHAR's dividend yield?
PHARMING GROUP NV offers a dividend yield of 0.00%.
What is PHAR's Quality Score?
Our AI rates PHAR's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PHAR?
Our AI Timing Score for PHAR is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PHAR belong to?
PHARMING GROUP NV is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
PHAR AI Analysis Summary
Our AI summary for PHAR: PHARMING GROUP NV (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 43.37, ROE of 4.58%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 10.08
Price
-0.67
(-6.23%)
Day Change
|
|
|---|
PHAR, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROE is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
2962
|
| Magic Formula Rank by ROE |
2962
|
| Magic Formula Rank by ROIC |
2310
|
| Price | 10.08 |
| PBV / Sector |
2.83 / 5.20
|
| Earning Per Share | 0.16 |
| PE / Sector |
43.37 / 19.97
|
| PEG or PE/Growth / Sector |
-0.42 / 1.22
|
| Average 1M Daily Value |
0.11 M
GREAT
|
| Average 1W Daily Value |
0.19 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:19 |
| Symbol | PHAR |
| Name | PHARMING GROUP NV |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 70.78 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 760.86 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Darwinweg 24, Leiden, Netherlands, 2333 CR
Phone: 31 71 524 7400
Website: https://www.pharming.com
Employees: 407
Sector: Healthcare >> Biotechnology
Description: Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap
Google